TNYA Insider Trading
Insider Ownership Percentage: 32.76%
Insider Buying (Last 12 Months): $24,999,998.80
Insider Selling (Last 12 Months): $71,850.01
Tenaya Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Tenaya Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Tenaya Therapeutics Share Price & Price History
Current Price: $0.70
Price Change: ▲ Price Increase of +0.0287 (4.28%)
As of 03/14/2025 05:00 PM ET
Tenaya Therapeutics Insider Trading History
Tenaya Therapeutics Institutional Trading History
Data available starting January 2016
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Read More on Tenaya Therapeutics
Volume
5,573,205 shs
Average Volume
2,061,057 shs
Market Capitalization
$61.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.83
Who are the company insiders with the largest holdings of Tenaya Therapeutics?
Who are the major institutional investors of Tenaya Therapeutics?
Which major investors are selling Tenaya Therapeutics stock?
Within the previous quarter, TNYA stock was sold by these institutional investors:
- Price T Rowe Associates Inc. MD
- Barclays PLC
- Squarepoint Ops LLC
- Millennium Management LLC
- XTX Topco Ltd
- Geode Capital Management LLC
- Dimensional Fund Advisors LP
- Bank of America Corp DE
Within the last year, company insiders that have sold Tenaya Therapeutics company stock include:
- Group Gp Lp Column III (Major Shareholder)
- Faraz Ali (CEO)
- Timothy Hoey (Insider)
- Whittemore Tingley (Insider)
Learn More investors selling Tenaya Therapeutics stock.
Which major investors are buying Tenaya Therapeutics stock?
During the last quarter, TNYA stock was purchased by institutional investors including:
- JPMorgan Chase & Co.
- Trustees of Columbia University in the City of New York
- Virtu Financial LLC
- Deutsche Bank AG
- Sei Investments Co.
- Nuveen Asset Management LLC
- abrdn plc
- Commonwealth Equity Services LLC